- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06630351
Group Meaning-Centered Psychotherapy for the Improvement of Wellbeing in Caregivers of Patients With Serious Illness
Group Meaning-Centered Psychotherapy for Caregivers of Patients With Serious Life-Limiting Illness
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVES:
I. Determine feasibility as measured by total number of caregivers enrolled in 2 years (modification to extend study another year), adherence (75% of the enrolled participants will complete at least 6 of the 8 MCP groups).
II. Determine acceptability as measured by satisfaction with the research process, as measured by the Was It Worth It (WiWi 2.0) questionnaire.
III. To evaluate preliminary efficacy of group MCP-C for personal meaning as measured by Life Attitude Profile-Revised (LAP-R), spiritual wellbeing as measured by Functional Assessment of Chronic Illness Therapy (FACIT) Spiritual Well-Being Scale (SWBS), depression and anxiety symptoms as measured by Hospital Anxiety and Depression Scale (HADS), meaning in caregiving as measured by Attitudes Towards Caregiving Scale (ATCS), social support as measured by Duke-University of North Carolina (UNC) Functional Social Support Questionnaire (FSSQ), benefit finding as measured by Benefit Finding Scale (BFS).
IV. Determine participants' perceptions of their experience with the intervention, including potential benefits they experienced, which components had the greatest impact, and whether they would suggest any changes to the intervention.
OUTLINE:
Caregivers participate in MCP-C virtual group discussion sessions over 90 minutes each and complete reading exercises and workbook assignments once weekly for 8 weeks throughout the study.
After completion of study intervention, caregivers are followed up at 2 months.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Jacksonville, Florida, United States, 32224-9980
- Mayo Clinic in Florida
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic in Rochester
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age >= 18 years
- English fluency
- No diagnosed severe cognitive impairment
- Caregiver of a patient with a diagnosis of advanced, solid tumor cancer (stage III/stage IV), caregivers supporting a patient with a serious life-limiting illness
- Provide written (paper or electronic) informed consent
- Ability to complete questionnaire(s) by themselves or with assistance
- Patient baseline distress score >= 4/10
- Have ability to utilize the technology to participate in virtual groups
Exclusion Criteria:
- As determined through self-report, those diagnosed with a history of a psychotic episode will be excluded
- Other psychological co-morbidities such as untreated schizophrenia, bipolar disease
- Cognitive impairment likely to interfere with participation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Supportive Care (MCP-C)
Caregivers participate in MCP-C virtual group discussion sessions over 90 minutes each and complete reading exercises and workbook assignments once weekly for 8 weeks throughout the study.
|
Ancillary studies
Ancillary studies
Participate in MCP-C
Other Names:
Participate in virtual group discussions
Other Names:
Receive reading exercises and workbook materials
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility of Meaning-Centered Psychotherapy for Caregivers (MCP-C) intervention
Time Frame: Up to 1 year
|
Feasibility will be measured by numbers and percentages of participant recruitment, enrollment, accrual, and retention of participants in the MCP-C intervention.
Findings will be summarized using estimates and corresponding 95% confidence intervals.
|
Up to 1 year
|
|
Acceptability of MCP-C intervention
Time Frame: 4 months (2 months post intervention)
|
Acceptability will be measured by the Was It Worth It (WIWI) Questionnaire.
The WIWI consists of 7 questions, 3 answered with yes/no/uncertain, two answered on a 3-point scale (i.e., improved, stayed the same, or got worse), one open-ended/fill-in-the-blank question, and one yes/no question.
|
4 months (2 months post intervention)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in personal meaning - LAP-R
Time Frame: Baseline, 8 weeks (post intervention), 4 months (2 months post intervention)
|
The Life Attitude Profile-Revised (LAP-R) is a 48-item scale that measures a person's life attitude and meaning in life.
The LAP-R is scored on a 7-point Likert scale, with a minimum score of 30 and a maximum score of 210.
A higher score indicates a greater sense of meaning in life and a more positive attitude towards life.
|
Baseline, 8 weeks (post intervention), 4 months (2 months post intervention)
|
|
Change in spiritual well-being - FACIT-Sp-12
Time Frame: Baseline, 8 weeks (post intervention), 4 months (2 months post intervention)
|
Spiritual well-being will be assessed using the Functional Assessment of Chronic Illness Therapy Spiritual Well-Being Scale (FACIT-Sp-12), a 12-item self-report measure with a total score range of 0-48, with higher scores indicating a greater level of spiritual well-being.
items are answered on a scale of 0-4 where 0=Not at all, 1=A little bit, 2=Somewhat, 3=Quite a bit, and 4=Very much.
|
Baseline, 8 weeks (post intervention), 4 months (2 months post intervention)
|
|
Changes in anxiety and depression - HADS
Time Frame: Baseline, 8 weeks (post intervention), 4 months (2 months post intervention)
|
Change in anxiety and depression will be assessed using the Hospital Anxiety and Depression Scale (HADS).
The HADS is a 14-item self-rated questionnaire with depression and anxiety subscales both ranging from 0 to 21, categorized as: normal 0-7, mild 8-10, moderate 11-14, and severe 15-21.
Items are answered on a scale of 0-3 with varying responses for each question (e.g., very much/quite a lot/not very much/not at all or often/sometimes/not often/very seldom).
|
Baseline, 8 weeks (post intervention), 4 months (2 months post intervention)
|
|
Change in attitude toward caregiving - ATCS
Time Frame: Baseline, 8 weeks (post intervention), 4 months (2 months post intervention)
|
Change in attitude toward caregiving will be assessed using the Attitudes Towards Caregiving Scale ( ATCS), a 43-item 5-point Likert-type measure of ways caregivers find meaning through caregiving.
The ATCS yields an overall (range 43-215) and three subscale [loss/powerlessness (range 19-96), provisional meaning (range 19-96), and ultimate meaning (range 5-25)] scores, with higher scores indicating higher overall meaning.
Items are answered with one of 5 responses: strongly agree, agree, undecided, disagree, or strongly disagree.
|
Baseline, 8 weeks (post intervention), 4 months (2 months post intervention)
|
|
Change in perception of social support - Duke-UNC FSSQ
Time Frame: Baseline, 8 weeks (post intervention), 4 months (2 months post intervention)
|
Change in perception of social support will be assessed using the Duke/University of North Caroling (UNC) Functional Social Support Questionnaire (FSSQ), an 8-item measure of social support that generates a total score (range 0-44).
Higher scores generally indicate a higher degree of satisfaction related to social support.
Items are answered on a scale of 5-1 where 5=as much as I would like; 4=almost as much as I would like; 3=some, but would like more; 2=less than i would like, and 1=much less than I would like.
|
Baseline, 8 weeks (post intervention), 4 months (2 months post intervention)
|
|
Change in benefit-finding - BFS
Time Frame: Baseline, 8 weeks (post intervention), 4 months (2 months post intervention)
|
Change in perception of benefit will be assessed using the Benefit Finding Scale (BFS), a 17-item measure of perceived benefits adapted from Behr's Positive Contributions Scale for breast cancer, modified for caregiving.
It yields a total score (range 17-85) with higher scores indicating greater benefit finding.
Items are answered with one of 5 responses: not at all, a little bit, somewhat, quite a bit, or very much.
|
Baseline, 8 weeks (post intervention), 4 months (2 months post intervention)
|
|
Change in Cancer Support Source Caregiver-18+ score
Time Frame: Baseline, 8 weeks (post intervention), 4 months (2 months post intervention)
|
The Cancer Support Source-Caregiver (CSS-Caregiver) is an 18-item questionnaire used to assess demands of cancer caregiving.
Participants rate items of concern on a scale of 0 (not at all) to 4 (very seriously).
A higher score indicates an item is of greater concern.
Higher overall scores indicate higher levels of stress.
|
Baseline, 8 weeks (post intervention), 4 months (2 months post intervention)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Deirdre R. Pachman, MD, Mayo Clinic in Rochester
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Health Care Quality, Access, and Evaluation
- Investigative Techniques
- Epidemiologic Methods
- Data Collection
- Health Care Evaluation Mechanisms
- Quality of Health Care
- Public Health
- Environment and Public Health
- Health Services
- Health Care Facilities Workforce and Services
- Preventive Health Services
- Socioeconomic Factors
- Population Characteristics
- Psychotherapy
- Behavioral Disciplines and Activities
- Health Education
- Interviews as Topic
- Educational Status
- Behavior Therapy
- Health Promotion
Other Study ID Numbers
- 24-004250 (Other Identifier: Mayo Clinic Institutional Review Board)
- NCI-2024-07626 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Malignant Solid Neoplasm
-
University of California, San FranciscoCompletedIntegrative Palliative Care/Psycho-Oncology Telehealth Intervention in Patients With Advanced CancerAdvanced Malignant Solid Neoplasm | Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterTerminatedLocally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
Ronald LevyBristol-Myers SquibbCompletedAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Extracranial Solid NeoplasmUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Rare Malignant Solid Neoplasm | Rare Malignant Solid Neoplasm | Refractory Rare Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Liver | Unresectable Solid NeoplasmUnited States, Canada
-
M.D. Anderson Cancer CenterTerminatedAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterCompletedAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid NeoplasmUnited States
Clinical Trials on Questionnaire Administration
-
Fondazione Don Carlo Gnocchi OnlusCompleted
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
Hospital Clínico Universitario de ValladolidRed Centinela Sanitaria de Castilla y León (RCSCYL); Centro Nacional de Gripe... and other collaboratorsRecruitingMigraine | Headache Disorders | Viral Infection | Influenza -Like Illness | Head PainSpain
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | COVID-19 Infection | Hereditary Breast CarcinomaUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingAdvanced Malignant Solid Neoplasm | Hematopoietic and Lymphoid System NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Plasma Cell Myeloma | Caregiver | Recurrent LeukemiaUnited States
-
Gulseren Demir KarakilicCompletedMusculoskeletal Diseases | Chronic PainTurkey (Türkiye)
-
I.M. Sechenov First Moscow State Medical UniversityAgency of Social Information St. PetersburgActive, not recruiting
-
I.M. Sechenov First Moscow State Medical UniversityActive, not recruitingShoulder ArthropathyRussian Federation
-
Karolinska University HospitalSahlgrenska University Hospital, Sweden; University Hospital, Linkoeping; Skane...Active, not recruitingQuality of Life | Vulvar CancerSweden